Clinical Trial Detail

NCT ID NCT00114738
Title EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

mantle cell lymphoma

Therapies

Cyclophosphamide + Doxorubicin + Etoposide + Methylprednisolone + Rituximab + Vincristine Sulfate

Rituximab

Bortezomib

Age Groups: adult

No variant requirements are available.